FCC seeks to stop robocalls passing through caller ID authentication in older technology
Mass recordings promoting or selling something are illegal unless the person gives permission to be contacted.
But fraudsters have been able to pass through older non-IP technology and avoid digital fingerprints. These include cellphones and wired phones often transmitting small amounts of data infrequently.
On Monday, Federal Communications Commission panelists by a 4-0 vote moved forward to make sure the digital IDs are not washed off of any part of the call path.
They approved a Notice of Proposed Rulemaking to establish criteria for evaluating whether frameworks meet the TRACED Act standards. Commissioners want providers to regularly certify their implementation and would give them two years to comply after adoption of the new rule.
The agency is seeking comment on implementation of caller ID authentication solutions and is trying to determine if this "opens the door for further improvements down the road," the agency said in a news release.
For the last four years, the FCC has delayed the TRACED Act's deadline for carriers to implement an authentication framework for non-IP calls.
"The STIR/SHAKEN caller ID authentication framework is a critical element -- long championed by the Commission -- for tracking, blocking, and warning customers about malicious robocalls," a news release said.
The technology uses a caller ID system to verify whether calls on a provider's network are truly coming from the number on display.
In 2021, major U.S. phone providers -- including AT&T, Verizon, T-Mobile and Comcast -- were ordered to implement STIR/SHAKEN technology to prevent rampant spam calls.
STIR/SHAKEN are acronyms for the Secure Telephone Identity Revisited and Signature-based Handling of Asserted Information Using Tokens standards, with STIR representing the protocol and SHAKEN the framework for tracking robocalls.
The FAA has been trying to crack down on robocallers.
Unwanted calls dropped for the third straight year, according to data released by the Federal Trade Commission in November 2024.
The 2024 edition of the Federal Trade Commission's Do Not Call Registry Data Book, first created in 2003, shows complaints down by more than half since 2021. They were 1.1 million illegal robocalls last year, down from 1.2 million the year before and 3.4 million in 2021.
The registry allows Americans to add their information to a list, prohibiting them from being contacted by telemarketers.
"In the years to come, it will be critical we continue this progress by confronting not only telemarketers but those firms who knowingly profit from scam calls," FTC Bureau of Consumer Protection Director Sam Levine said in 2024.
In December, the FCC proposed a $299.9 million fine for Roy Cox Jr. and Michael Aaron Jones, who robocalled more than 550 million people offering misleading vehicle warranty services. TheFCC directed companies to book the calls.
Copyright 2025 UPI News Corporation. All Rights Reserved.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
UPI
14 minutes ago
- UPI
South Korea's Samsung Biologics, Celltrion log stellar performances
1 of 2 | South Korean biopharmaceutical contract manufacturer Samsung Biologics posted a stellar performance in the first half of this year. Photo courtesy of Samsung Biologics SEOUL, July 24 (UPI) -- The South Korean economy struggles as the country's gross domestic product growth rate is feared to more than halve to less than 1% this year, compared to 2% for 2024. However, its defense and shipbuilding industries are faring well. Also among the high achievers are biopharmaceutical contract manufacturers, including Samsung Biologics and Celltrion. Samsung Biologics, one of the world's largest contract development and manufacturing organizations, or CDMOs, announced Wednesday that it posted record-high $1.88 billion in sales during the first six months of 2025, up 21.3% from a year earlier. Its operating profit amounted to $700 million, up 46.75%. The company also said that it has signed contracts worth $2.4 billion in the first half of the year, which is more than 60% of its total annual order volume for 2024. "As global demand for CDMO services continues to rise, we are rapidly expanding our production capacity," Samsung Biologics said in a statement. "Backed by our world-class CDMO capabilities, we plan to intensify our efforts to win more orders, particularly targeting the world's top 40 pharmaceutical companies." Samsung's local rival, Celltrion, is likewise seeing impressive results. The outfit announced Tuesday that its first-half turnover stood at $1.31 billion, up 11.9% year-on-year. Its operating income more than tripled to $285 million. The company's sales for this year are expected to top $3 billion for the first time, and its bottom line is projected to near the $1 billion mark. Observers have positive outlooks for the two powerhouses. "Samsung Biologics is beefing up its global competitiveness through the second campus, which includes plants five to eight," KB Securities researcher Kim Hye-min said in a market report. "The company is also expanding its capabilities beyond traditional monoclonal antibody-focused CDMO services to next-generation modalities and pre-filled syringes," she noted. Prefilled syringe manufacturing means that Samsung Biologics rolls out drugs in ready-to-inject formats. Global pharmaceutical clients tend to request this for chronic diseases or biologic treatments. Regarding Celltrion, Heungkuk Securities analyst Lee Ji-won said in a recent report that this year would be a pivotal point for the company's profit growth momentum. "Celltrion is predicted to demonstrate a significant year-on-year increase in profits, driven by the solid performance of newly launched high-margin biosimilars," Lee said. Experts said the CDMO businessm which is based on outsourced manufacturing, is an area in which Korean companies have advantages. "Although the Korean economy languishes due to various reasons this year, the biopharmaceutical outsourcing business is likely to rack up stellar performances for the time being. Samsung Biologics and Celltrion will spearhead the trend," Seoul-based business tracker Leaders Index CEO Park Ju-gun told UPI. "Samsung Biologics has already become an established player in the market, favored by global biopharmaceutical giants thanks to its cost competitiveness and quick delivery. Celltrion is also trying hard to become a big name in the market," he said. Economic analyst Kim Joon-Kyung, formerly vice chairman at Deloitte Consulting Korea, agreed. "First of all, the CDMO industry is promising. And from the perspective of Samsung, the business shares many characteristics with semiconductor production. Hence, the group had a good reason to tap into the CDMO sector," Kim said in a phone interview. "Celltrion did not have such advantages. But the company secured technological edges early on, which is quite an achievement. That's why Celltrion is showing solid performances now," he said. Samsung Electronics, the mother company of Samsung Biologics, is the world's largest maker of memory chips. According to U.S. market intelligence firm BCC Research, the global CDMO market is expected to expand to $191.6 billion by 2029 from $136.6 billion last year based on mounting demand for outsourced drug development and manufacturing. Other biopharmaceutical companies in Korea also are striving to tap into the lucrative CDMO business, including SK Bioscience and Lotte Biologics. Toward that end, SK Bioscience acquired a controlling stake in IDT Biologika of Germany, which is one of the top 10 global vaccine CDMOs, late last year. Lotte Biologics has launched operations of its antibody-drug conjugate facility at its Syracuse Bio Campus in the United States. The company also is preparing its first plant located just west of Seoul, aiming to begin commercial production in 2027.
UPI
15 minutes ago
- UPI
U.K. and India sign 'Comprehensive Economic and Trade Agreement'
British Prime Minister Keir Starmer and India's Prime Minister Narendra Modi met on Thursday to sign a trade agreement between the two nations. Pool Photo by Chris J. Ratcliffe/EPA July 24 (UPI) -- Britain and India agreed to a free trade agreement between their two nations Thursday. "A new chapter begins today in the India-U.K. economic partnership," said Indian Prime Minister Narendra Modi on his social media platform Thursday. "The signing of the Comprehensive Economic and Trade Agreement reflects our shared commitment to enhancing trade, driving inclusive growth and creating opportunities for farmers, women, youth, [Micro, Small, and Medium Enterprises] and professionals." The deal is expected to inject over $6.5 billion into the British economy and create more than $8 billion by way of investments from companies based in both countries. "Our landmark trade deal with India is a major win for Britain," British Prime Minister Keir Starmer posted to X Thursday. "This is about putting more money in the pockets of hardworking Brits and helping families with the cost of living." Modi and Starmer met and held a press conference on Thursday at Starmer's country house in Buckinghamshire County. Job growth in sectors such as technology, aerospace and manufacturing is expected, as noted in a press release from the U.K. Thursday. "Thanks to the deal, British workers will enjoy a collective uplift in wages of [nearly $3 billion] each year and could also see cheaper prices and more choice on clothes, shoes, and food products," the statement said. Scottish Labor Party MP Ian Murray praised the deal online Thursday. "The India Trade Deal is great news for Scottish jobs and business," Murray posted to X. "The landmark agreement will deliver [an over $257 million] boost for the Scottish economy as part of the Plan for Change." The U.K. Plan for Change are the current goals sought to achieve by the current British government. The agreement is also anticipated to make imported goods cheaper for Indian consumers, according to a press release from the Indian government Thursday, which would include luxury cars, gin, Scotch whisky, cosmetics and medical devices. "Within the next two years, India's leather industry is projected to increase its market share in the U.K. by 5%," the release said. Bharti Enterprises conglomerate Founder and Chairman Sunil Bharti Mittal accompanied Modi as a delegate to meet with Starmer in England. "This agreement establishes a modern, forward-looking partnership that will stimulate innovation, ease market access, and foster investment," said Mittal. "Businesses in both India and the U.K. stand to benefit as this lays the foundation for expanding bilateral cooperation across key growth sectors." Tariffs between the U.K. and India will also lessen, as Britain will reduce levies on 99% of Indian exports, while India will decrease tariffs on 90% of British goods. The trade deal will "add momentum to the 'Make in India' led growth and export promotion," said Modi Thursday. "The future indeed holds the promise of greater prosperity and deeper ties between our nations."
Miami Herald
44 minutes ago
- Miami Herald
EU-China summit exposes tensions over trade imbalances, Ukraine
July 24 (UPI) -- A European Union-China summit in Beijing on Thursday saw Chinese President Xi Jinping's call for closer ties met with a reality check from European Commission President Ursula von der Leyen over China's $359 billion trade surplus with the EU. Xi told the high-level gathering, marking 50 years of diplomatic relations between Brussels and Beijing, that rising current geopolitical frictions demanded the two sides strengthen their "mutually beneficial" relationship. "The more severe and complex the international situation is, the more China and the EU should strengthen communication, enhance mutual trust, and deepen cooperation," Xi told the EU delegation headed by von der Leyen and European Council President Antonio Costa. Telling them that the problems Europe was facing "do not come from China," Xi urged the EU to deal with tensions and disagreements properly, keep its market open and refrain from resorting to measures targeting trade, including tariffs. However, Von der Leyen pushed back, saying relations were at a critical point where the Chinese leadership needed to prioritize the huge trade imbalance between the EU and China. "As our cooperation has deepened, so have the imbalances. We have reached an inflection point. Rebalancing our bilateral relations is essential. Because to be sustainable, relations need to be mutually beneficial. To achieve this, it is vital for China and Europe to acknowledge our respective concerns and come forward with real solutions," she said. Trade tensions have taken a toll on the relationship after Brussels, accusing China of unfair subsidies, hiked tariffs on Chinese electric vehicles while Beijing targeted imports of European brandy, pork, and dairy products with anti-dumping investigations. China has also restricted government purchasing of EU-made medical devices in retaliation for Brussels making it much more difficult for Chinese suppliers to bid for EU medical equipment contracts. This was against a backdrop of a trade relationship in which Chinese exports to the EU reached $609.4 billion in 2024, while EU exports to China were just $250.4 billion. Official Chinese data for the first half of this year show the goods-trade surplus up 21% on the same period in 2024, although the Chinese totals are somewhat lower than the EU's figures. A rapprochement hoped for by Beijing between the world's second- and third-largest trading blocs, both at the forefront of U.S. President Donald Trump's blanket tariff hikes, has gradually evaporated amid the airing of grievances. That saw the summit, which was originally planned to run through Friday, cut to one day. In meetings with Xi in the morning and Chinese Premier Li Qiang after lunch, von der Leyen and Costa raised not only the trade issue but also China's backing for Russia in the Ukraine war and end export controls on rare earth minerals, of which China has among the world's largest reserves. Von der Leyen has previously accused China of leveraging its "quasi-monopoly on rare earths not only as a bargaining chip, but also weaponizing it to undermine competitors in key industries." Costa told Xi he needed to use China's sway to push Moscow to halt the war. The two sides did, however, manage to see eye-to-eye on the climate, issuing a joint communique vowing to "demonstrate leadership together" and develop proposals to combat the emissions causing global warming in time for this year's COP, the U.N. Climate Change Conference, in Brazil in November. Copyright 2025 UPI News Corporation. All Rights Reserved.
